Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MTTP | P55157 | 10/20 | 0.44 |
| ▸ | APOB | P04114 | 7/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | UGCG | Q16739 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490959 | 0.90 | TP53 (0.43) | TP53LMNAMTTPAPOBMAPT | |
| SCHEMBL6800205 | 0.90 | TP53 (0.47) | TP53LMNAMTTPAPOBSMO | |
| SCHEMBL7080685 | 0.89 | TP53 (0.47) | TP53LMNAMTTPAPOBMAPT | |
| SCHEMBL6795017 | 0.88 | TP53 (0.50) | TP53LMNAMTTPAPOBMAPT | |
| SCHEMBL6799168 | 0.86 | TP53 (0.49) | TP53LMNAMTTPAPOBSMO | |
| SCHEMBL6789234 | 0.86 | SMO (0.47) | MTTPAPOBSMOUGCGRXFP1 | |
| SCHEMBL6793408 | 0.86 | TP53 (0.43) | TP53LMNAMTTPAPOBSMO | |
| SCHEMBL6795504 | 0.85 | MTTP (0.42) | TP53MTTPAPOBSMOMAPT | |
| SCHEMBL6800702 | 0.85 | RAB9A (0.47) | TP53LMNAMTTPAPOBSMO | |
| SCHEMBL6680191 | 0.84 | LMNA (0.38) | TP53LMNAMAPTRXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | TP53 4865/4885LMNA 1239/4885MTTP 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.